Spondyloarthritis & psoriatic arthritis
Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy
Authors' conclusion
High BMI decreases the odds for MDA in PsA, mainly affecting subjective disease measures. This effect is most pronounced in patients treated with TNFi (except infliximab).
Study context
- Population
- Patients with psoriatic arthritis (PsA) in the Gladman Krembil PsA Program cohort with available body mass index (BMI) measurement over follow-up (mean age 44.7 years, 56% male, mean BMI 28.8 kg/m²)
- Participants
- 1,291 patients
- Exposure
- Higher vs lower BMI
- Outcome
- MDA state over time
Methodological detailsGladman Krembil PsA Program cohort, multivariable generalized estimating equations and linear mixed models, subgroup analyses across six drug classes
- Gladman Krembil PsA Program cohort
- Multivariable generalized estimating equations and linear mixed models
- Subgroup analyses across six drug classes
Main finding
As reported in the abstract
MDA, per higher BMI
Higher BMI independently associated with lower odds for minimal disease activity (MDA)
MV OR 0.97
95% CI 0.94, 0.99
Observational data: associations, not effects.
Further findings
MDA components
- BMI negatively associated with all MDA components except swollen joint count
MDA in TNFi-treated patients excluding infliximab (subgroup), BMI at drug initiation
- Higher BMI associated with reduced odds for MDA
- Multivariable (MV) OR 0.94 (95% CI 0.92, 0.97)
- Longitudinal BMI assessment similarly showed reduced MDA odds with TNFi (excluding infliximab)
MDA in IL-17i, IL-12/23i, IL-23i or Janus kinase inhibitors (JAKi)-treated patients (subgroups)
- No significant effect of BMI
Original publication
Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy. Rheumatology (Oxford). Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →